Fresenius SE Gross Profit 2016-2023 | FSNUY
Fresenius SE annual/quarterly gross profit history and growth rate from 2016 to 2023. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Fresenius SE gross profit for the quarter ending September 30, 2023 was $1.384B, a 49.18% decline year-over-year.
- Fresenius SE gross profit for the twelve months ending September 30, 2023 was $9.479B, a 17.94% decline year-over-year.
- Fresenius SE annual gross profit for 2022 was $11.3B, a 7.37% decline from 2021.
- Fresenius SE annual gross profit for 2021 was $12.199B, a 3.52% increase from 2020.
- Fresenius SE annual gross profit for 2020 was $11.784B, a 1.68% increase from 2019.
Fresenius SE Annual Gross Profit
(Millions of US $) |
| 2022 |
$11,300 |
| 2021 |
$12,199 |
| 2020 |
$11,784 |
| 2019 |
$11,590 |
| 2018 |
$11,614 |
| 2017 |
$11,841 |
| 2016 |
$10,101 |
| 2015 |
$9,476 |
Fresenius SE Quarterly Gross Profit
(Millions of US $) |
| 2023-09-30 |
$1,384 |
| 2023-06-30 |
$2,544 |
| 2023-03-31 |
$2,695 |
| 2022-12-31 |
$2,855 |
| 2022-09-30 |
$2,724 |
| 2022-06-30 |
$2,850 |
| 2022-03-31 |
$2,871 |
| 2021-12-31 |
$3,106 |
| 2021-09-30 |
$2,975 |
| 2021-06-30 |
$3,154 |
| 2021-03-31 |
$2,963 |
| 2020-12-31 |
$3,088 |
| 2020-09-30 |
$2,927 |
| 2020-06-30 |
$2,809 |
| 2020-03-31 |
$2,960 |
| 2019-12-31 |
$3,016 |
| 2019-09-30 |
$2,855 |
| 2019-06-30 |
$2,875 |
| 2019-03-31 |
$2,844 |
| 2018-12-31 |
$2,997 |
| 2018-09-30 |
$2,784 |
| 2018-06-30 |
$2,960 |
| 2018-03-31 |
$2,874 |
| 2017-12-31 |
$3,139 |
| 2017-09-30 |
$2,928 |
| 2017-06-30 |
$2,905 |
| 2017-03-31 |
$2,870 |
| 2016-12-31 |
$2,698 |
| 2016-09-30 |
$2,554 |
| 2016-06-30 |
$2,487 |
| 2016-03-31 |
$2,362 |
| 2015-12-31 |
$7,951 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$16.392B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
